Immunai
Immunai is an Israeli-founded private VC-backed biotech AI startup building immune system intelligence platforms for advanced therapeutic development.
Visit WebsiteCompany Overview
Immunai develops AI and single-cell biology infrastructure to model immune behavior, identify therapeutic targets, and accelerate development decisions in immunology programs. Its platform combines high-dimensional biological data with machine learning for translational insight.
The company is privately held and venture-backed, with substantial institutional financing and cross-border operations. It is Israeli-founded and active in strategic biotech and computational biology segments.
Dual-use relevance is medium: immune intelligence platforms primarily serve civilian biopharma innovation but can also inform defense-adjacent biodefense preparedness and medical response planning workflows.
Dual-Use Assessment
Immune system AI intelligence is dual-use for therapeutic development and defense-adjacent biodefense and readiness-oriented biomedical planning.
Key Technologies
- Single-cell immune data modeling
- AI-driven immune behavior inference
- Therapeutic target identification analytics
- Computational immunology decision platforms
- Biological knowledge graph integration
Use Cases & Applications
- Accelerating immunology drug development decisions
- Improving target confidence in complex immune pathways
- Supporting translational biomedical research planning
- Enabling rapid hypothesis testing in immune response contexts
- Contributing data intelligence for preparedness-oriented health research
Strategic Value to U.S.-Israel Alliance
Enhances biomedical decision quality in domains where immune intelligence can influence therapeutic and preparedness outcomes.
Interested in this startup?
Learn more about our investment approach or get in touch to discuss opportunities in dual-use technology.